Antimicrobial resistance (AMR) is a major public-health threat, with low- and middle-income countries (LMICs) facing a disproportionate burden because high infectious-disease incidence often coexists with limited diagnostic capacity, inconsistent antimicrobial stewardship, inadequate water and sanitation, and fragmented surveillance. Conventional culture and antimicrobial-susceptibility testing remain essential for patient care and national AMR monitoring, but they provide limited resolution for identifying resistance mechanisms, reconstructing transmission, and characterizing environmental reservoirs. Whole-genome sequencing (WGS) and metagenomic approaches can address several of these gaps when they are integrated with, rather than substituted for, high-quality phenotypic surveillance. WGS can identify resistance determinants, virulence factors, mobile genetic elements, and closely related lineages, supporting outbreak investigation and molecular epidemiology. Metagenomic sequencing can characterize microbial communities and resistomes directly from complex samples such as wastewater, enabling culture-independent surveillance across human, animal, and environmental compartments. Evidence from Nigeria, Peru, and Pakistan illustrates how genomic methods can reveal mobile-element-associated resistance, community-level sewage resistomes, and clonal dissemination of extensively drug-resistant pathogens. However, benefits are constrained by sequencing and reagent costs, supply-chain instability, laboratory infrastructure, bioinformatics capacity, data governance, standardization, and long-term financing. We argue that genomic AMR surveillance in LMICs is most feasible when implemented as a tiered system: strengthened routine microbiology and isolate archiving at sentinel sites, targeted WGS for priority organisms and outbreaks, regional sequencing and bioinformatics hubs, and strategically selected metagenomic surveillance for environmental and One Health questions. Sustainable implementation requires local workforce development, interoperable data systems, quality assurance, and explicit links between genomic findings and public-health decisions.